Optimization techniques for novel c-Met kinase inhibitors

Synthesis and bioevaluation study of novel N -methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors

(2018) Linxiao Wang et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents

(2018) Linxiao Wang et al.   BIOORGANIC CHEMISTRY

Fluorescence-guided surgery of cancer: applications, tools and perspectives

(2018) Philip S Low et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Synthesis and antiproliferative activity of pyrrolo[2,3- b ]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety

(2018) Qidong Tang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Recent advances in the discovery of small molecule c-Met Kinase inhibitors

(2018) Palak K. Parikh et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

(2018) John Heymach et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted radiotherapy for early breast cancer

(2018) Jayant S Vaidya et al.   LANCET

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

(2018) Lorenza Rimassa et al.   LANCET ONCOLOGY

Kinase-targeted cancer therapies: progress, challenges and future directions

(2018) Khushwant S. Bhullar et al.   Molecular Cancer

Predicting tyrosinase inhibition by 3D QSAR pharmacophore models and designing potential tyrosinase inhibitors from Traditional Chinese medicine database

(2018) Hongwei Gao   PHYTOMEDICINE

Furanone derivatives as new inhibitors of CDC7 kinase: development of structure activity relationship model using 3D QSAR, molecular docking, and in silico ADMET

(2018) Adnane Aouidate et al.   STRUCTURAL CHEMISTRY

Identification of 3-substituted-6-(1-(1 H -[1,2,3]triazolo[4,5- b ]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization

(2017) Fei Zhao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors

(2017) Qidong Tang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors

(2017) Lin Xiao Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques

(2017) Jing Li Wang et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale

(2017) Ravi Salgia   MOLECULAR CANCER THERAPEUTICS

A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

(2017) James I. Geller et al.   PEDIATRIC BLOOD & CANCER

Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives

(2017) Dong Lu et al.   ACS Medicinal Chemistry Letters

3D-QSAR and molecular docking analysis of (4-piperidinyl)-piperazines as acetyl-CoA carboxylases inhibitors

(2017) Udghosh Singh et al.   Arabian Journal of Chemistry

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196

(2017) Natasha B. Leighl et al.   Oncotarget

Natural product inhibitors of carbonic anhydrase I and II isoenzymes: osajin and pomiferin

(2017) Esra Dilek et al.   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).

(2017) Allen Lee Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

(2016) Eun-Young Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors

(2016) Wufu Zhu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery and optimization of a series of imidazo[4,5- b ]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal–epithelial transition factor (c-Met) protein kinase

(2016) Fei Zhao et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors

(2016) Xin Zhai et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold

(2016) Hong Cui et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors

(2016) Qidong Tang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells

(2016) Chi Hoon Park et al.   BMC CANCER

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

(2016) Daniel Rayson et al.   BREAST CANCER RESEARCH AND TREATMENT

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2016) Thomas C.C. Yau et al.   CLINICAL CANCER RESEARCH

MET inhibition and merestinib (LY-2801653) for cancer treatment

(2016) P.A. Prins et al.   DRUGS OF THE FUTURE

Design and synthesis of novel benzo[d]oxazol-2(3H)-one derivatives bearing 7-substituted-4-enthoxyquinoline moieties as c-Met kinase inhibitors

(2016) Dong Lu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase

(2016) Yang Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3′-bipyridine derivatives as potential c-met inhibitors

(2016) Sijia Zhao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- b ][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor

(2016) Zhengsheng Zhan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors

(2016) Ju Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Trends in the development of MET inhibitors for hepatocellular carcinoma

(2016) Hitomi S Okuma et al.   Future Oncology

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-typeKRASwho have received first-line systemic therapy

(2016) Cathy Eng et al.   INTERNATIONAL JOURNAL OF CANCER

3D-QSAR and molecular docking studies on designing inhibitors of the hepatitis C virus NS5B polymerase

(2016) Wenlian Li et al.   JOURNAL OF MOLECULAR STRUCTURE

3D-QSAR studies on 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4- carboxamide derivatives as HIV-1 integrase inhibitors

(2016) Saloni Patel et al.   Journal of the Taiwan Institute of Chemical Engineers

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

(2016) Alexander Drilon et al.   LANCET ONCOLOGY

Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors

(2016) Stephanie Hielscher-Michael et al.   Marine Drugs

Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis

(2015) Weiqiang Xing et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

(2015) Geoffrey I. Shapiro et al.   INVESTIGATIONAL NEW DRUGS

Design and Optimization of a Series of 1-Sulfonylpyrazolo[4,3-b]pyridines as Selective c-Met Inhibitors

(2015) Yuchi Ma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis

(2015) LIN YE et al.   Oncology Letters

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

(2015) Parag P. Patwardhan et al.   Oncotarget

Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth

(2015) Ning Xi et al.   CANCER RESEARCH

Abstract 2530: Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML

(2015) Yung Chang Hsu et al.   CANCER RESEARCH

A phase I study of cabozantinib (XL184) in patients with renal cell cancer

(2014) T. K. Choueiri et al.   ANNALS OF ONCOLOGY

Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors

(2014) Seung-Tae Kang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

(2014) S. M. Malik et al.   CLINICAL CANCER RESEARCH

Discovery of novel type II c-Met inhibitors based on BMS-777607

(2014) Wei Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold

(2014) Wei Zhang et al.   MOLECULES

Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma

(2014) Sahzene Yavuz et al.   THYROID

Synthesis and Biological Evaluation of 4-Phenoxy-6,7-disubstituted Quinolines Possessing Semicarbazone Scaffolds as Selective c-Met Inhibitors

(2013) Baohui Qi et al.   ARCHIV DER PHARMAZIE

Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors

(2013) Baohui Qi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors

(2013) Sai Li et al.   BIOORGANIC & MEDICINAL CHEMISTRY

KRC-327, a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity

(2013) Byung Hee Park et al.   CANCER LETTERS

Design, synthesis, and structure–activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents

(2013) Qidong Tang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

(2013) M. F. Burbridge et al.   MOLECULAR CANCER THERAPEUTICS

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors

(2012) Christiane M. Bode et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and structure–activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors

(2012) Jongkook Lee et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

O-Linked Triazolotriazines: Potent and Selective c-Met Inhibitors

(2012) Fang Chen et al.   ChemMedChem

Computer-Aided Drug Design of Falcipain Inhibitors: Virtual Screening, Structure–Activity Relationships, Hydration Site Thermodynamics, and Reactivity Analysis

(2012) Falgun Shah et al.   Journal of Chemical Information and Modeling

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

(2012) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors

(2011) Jae Wook Ryu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient

(2011) Sohei Yamamoto et al.   MODERN PATHOLOGY

Crizotinib

(2011) Alice T. Shaw et al.   NATURE REVIEWS DRUG DISCOVERY

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors

(2010) Sung Yun Cho et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors

(2009) Alessandro A. Boezio et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges

(2009) Xiangdong Liu et al.   TRENDS IN MOLECULAR MEDICINE

A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met

(2008) Cristina Basilico et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities

(2008) Kyoung Soon Kim et al.   JOURNAL OF MEDICINAL CHEMISTRY